Two Pieces of Good News for Amarin (AMRN) - Cantor Fitzgerald

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $35.00 price target on Amarin Corporation (NASDAQ: AMRN) as two pieces of good news further support their positive rating:

1) ACST announced that due to the unexpectedly large placebo response, TRILOGY 1 did not reach statistical significance.

2) Following the recommendation from an independent Data Monitoring Committee, AZN has decided to close the Phase III STRENGTH trial for Epanova (omega-3 carboxylic acids) due to its low likelihood of demonstrating a benefit to patients with mixed dyslipidaemia (MDL) who are at increased risk of cardiovascular (CV) disease.

"Therefore, AMRN has been the only company in its class with an outcomes study (REDUCE-IT) that has shown a statistically significant benefit in reducing CV disease," Chen commented. "We think the news today underscores our view that AMRN is an interesting asset in a consolidating space."

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $19.75 yesterday.

You May Also Be Interested In

• Cantor Fitzgerald Downgrades Better Home & Finance Holding (BETR) to Neutral
• Cantor Fitzgerald Upgrades WhiteFiber Inc (WYFI) to Overweight
• Cantor Fitzgerald Reiterates Overweight Rating on Global Net Lease (GNL)